Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) has been given an average rating of “Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, twelve have issued a buy rating and four have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $66.00.
SRRK has been the subject of a number of recent research reports. Barclays cut Scholar Rock from an “overweight” rating to a “cautious” rating in a report on Tuesday. Citigroup lifted their price objective on Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Piper Sandler lifted their price target on shares of Scholar Rock from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th.
Read Our Latest Stock Analysis on SRRK
Insider Buying and Selling at Scholar Rock
Hedge Funds Weigh In On Scholar Rock
Large investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in Scholar Rock by 20.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after purchasing an additional 242 shares during the last quarter. Values First Advisors Inc. raised its position in shares of Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after acquiring an additional 286 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Syon Capital LLC increased its position in Scholar Rock by 6.4% in the second quarter. Syon Capital LLC now owns 9,782 shares of the company’s stock worth $538,000 after purchasing an additional 588 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.
Scholar Rock Price Performance
NASDAQ:SRRK opened at $46.65 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The stock has a market cap of $5.68 billion, a P/E ratio of -13.52 and a beta of 0.67. The company has a fifty day moving average price of $52.84 and a 200 day moving average price of $49.63. Scholar Rock has a one year low of $27.07 and a one year high of $61.76.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.84). During the same period in the prior year, the business earned ($0.98) EPS. Analysts anticipate that Scholar Rock will post -3.24 earnings per share for the current year.
Scholar Rock Company Profile
Scholar Rock, Inc is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company’s approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.
Scholar Rock’s lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.
Recommended Stories
- Five stocks we like better than Scholar Rock
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
